1. ホーム
  2. 一覧
論文 特許

論文 - 一覧

  • 12 Hits
  • 検索条件 : 絞込み (MeSH = Class I Phosphatidylinositol 3-Kinases)
生物種 リソース名 タイトル
ヒト・動物細胞 Lu-134-A(RCB0466) , Lu-134-B(RCB0467) Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
ヒト・動物細胞 JHOC-5(RCB1520) A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
ヒト・動物細胞 HeLa(RCB0007) , Saos-2(RCB0428) Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways.
ヒト・動物細胞 JHOC-7(RCB1688) Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
ヒト・動物細胞 MKN1(RCB1003) Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.
ヒト・動物細胞 MKN1(RCB1003) , MKN45(RCB1001) , MKN7(RCB0999) , MKN74(RCB1002) PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
ヒト・動物細胞 JHOC-7(RCB1688) , JHOC-9(RCB2226) , HTOA(RCB0692) , JHOS-2(RCB1521) , JHOS-3(RCB1546) , JHOS-4(RCB1678) Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
ヒト・動物細胞 OCUB-F(RCB0882) mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
ヒト・動物細胞 JHOC-9(RCB2226) , JHOC-5(RCB1520) Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
ヒト・動物細胞 Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.
ヒト・動物細胞 KUSA-H1(RCB1990) , 9-15C(RCB2323) , TSt-4(RCB2116) The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
遺伝子材料 AxCAhPTEN1 (RDB02012) Suppression of Egr-1 transcription through targeting of the serum response factor by oncogenic H-Ras.